受进化标志启发的癌症预后生物标志物和药物靶点鉴定。

IF 7.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Discovery Today Pub Date : 2025-09-18 DOI:10.1016/j.drudis.2025.104479

Yang He, Chen-Wei Zhou, Zhi-Wen Zhang, Yuan Quan, Hong-Yu Zhang

{"title":"受进化标志启发的癌症预后生物标志物和药物靶点鉴定。","authors":"Yang He, Chen-Wei Zhou, Zhi-Wen Zhang, Yuan Quan, Hong-Yu Zhang","doi":"10.1016/j.drudis.2025.104479","DOIUrl":null,"url":null,"abstract":"<div><div>Identifying prognostic biomarkers and drug targets is important for cancer treatment. Accumulating evidence indicates that cancer progression reflects the reactivation of ancestral cellular programs, with evolutionarily ancient genes exerting a pivotal influence on tumor development. These ancient genes are markedly enriched among clinically validated biomarkers and therapeutic targets, highlighting their essential contribution to cancer pathogenesis and therapeutic development. The transcriptome age index (TAI) provides a quantitative framework to characterize transcriptome evolutionary dynamics, with demonstrated prognostic relevance across multiple cancer types. This review underscores the value of the TAI in shaping an evolutionary perspective for biomarker discovery and drug target identification, and considers its potential to advance precision oncology and future therapeutic development.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 11","pages":"Article 104479"},"PeriodicalIF":7.5000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evolutionary hallmark-inspired identification of prognostic biomarkers and drug targets for cancers\",\"authors\":\"Yang He, Chen-Wei Zhou, Zhi-Wen Zhang, Yuan Quan, Hong-Yu Zhang\",\"doi\":\"10.1016/j.drudis.2025.104479\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Identifying prognostic biomarkers and drug targets is important for cancer treatment. Accumulating evidence indicates that cancer progression reflects the reactivation of ancestral cellular programs, with evolutionarily ancient genes exerting a pivotal influence on tumor development. These ancient genes are markedly enriched among clinically validated biomarkers and therapeutic targets, highlighting their essential contribution to cancer pathogenesis and therapeutic development. The transcriptome age index (TAI) provides a quantitative framework to characterize transcriptome evolutionary dynamics, with demonstrated prognostic relevance across multiple cancer types. This review underscores the value of the TAI in shaping an evolutionary perspective for biomarker discovery and drug target identification, and considers its potential to advance precision oncology and future therapeutic development.</div></div>\",\"PeriodicalId\":301,\"journal\":{\"name\":\"Drug Discovery Today\",\"volume\":\"30 11\",\"pages\":\"Article 104479\"},\"PeriodicalIF\":7.5000,\"publicationDate\":\"2025-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Discovery Today\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1359644625001928\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359644625001928","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

确定预后生物标志物和药物靶点对癌症治疗非常重要。越来越多的证据表明，癌症的进展反映了祖先细胞程序的再激活，进化上古老的基因对肿瘤的发展发挥了关键的影响。这些古老的基因在临床验证的生物标志物和治疗靶点中显着丰富，突出了它们在癌症发病和治疗发展中的重要贡献。转录组年龄指数（TAI）提供了一个定量框架来表征转录组进化动力学，并证明了与多种癌症类型的预后相关。这篇综述强调了TAI在形成生物标志物发现和药物靶点鉴定的进化观点方面的价值，并认为它有可能推动精确肿瘤学和未来治疗发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Evolutionary hallmark-inspired identification of prognostic biomarkers and drug targets for cancers

查看原文本刊更多论文

Evolutionary hallmark-inspired identification of prognostic biomarkers and drug targets for cancers

Identifying prognostic biomarkers and drug targets is important for cancer treatment. Accumulating evidence indicates that cancer progression reflects the reactivation of ancestral cellular programs, with evolutionarily ancient genes exerting a pivotal influence on tumor development. These ancient genes are markedly enriched among clinically validated biomarkers and therapeutic targets, highlighting their essential contribution to cancer pathogenesis and therapeutic development. The transcriptome age index (TAI) provides a quantitative framework to characterize transcriptome evolutionary dynamics, with demonstrated prognostic relevance across multiple cancer types. This review underscores the value of the TAI in shaping an evolutionary perspective for biomarker discovery and drug target identification, and considers its potential to advance precision oncology and future therapeutic development.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drug Discovery Today 医学-药学

CiteScore

14.80

自引率

2.70%

发文量

293

审稿时长

6 months

期刊介绍： Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.